GRAIL, Inc. (GRAL): R&D Expense
$195.79M
Year ended 2025-12-31
$190.99M
Trailing 12 months to 2026-06-30
-15.9%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $195.79M | -39.3% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $322.38M | -4.8% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $338.75M | n/a | 2026-03-12, From 2023-01-01 |
| 2023-01-01, Fiscal 2022 | $329.58M | n/a | 2025-03-05, From 2022-01-03 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| GRAIL, Inc. (GRAL) | 2025-12-31 | $195.79M | -39.3% |
| Biodesix Inc (BDSX) | 2025-12-31 | $12.00M | +25.5% |
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $49.38M | +34.9% |
| Personalis, Inc. (PSNL) | 2025-12-31 | $50.26M | +2.8% |
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | $53.91M | +10.4% |
| Exagen Inc. (XGN) | 2025-12-31 | $6.25M | +16.4% |
| Castle Biosciences Inc (CSTL) | 2025-12-31 | $51.85M | -0.4% |
| CareDx, Inc. (CDNA) | 2025-12-31 | $71.43M | -1.5% |
| Veracyte, Inc. (VCYT) | 2025-12-31 | $70.81M | +2.2% |
Compare GRAL, BDSX, BLLN, PSNL side by side · Screen every company in Services-Medical Laboratories ↗